{"id":3537,"date":"2024-12-16T23:57:07","date_gmt":"2024-12-16T20:27:07","guid":{"rendered":"https:\/\/uro-med.ir\/prostate-cancer\/?p=3537"},"modified":"2025-05-14T01:24:30","modified_gmt":"2025-05-13T21:54:30","slug":"prostate-cancer-esmo-clinical-guidelines","status":"publish","type":"post","link":"https:\/\/uro-med.ir\/prostate-cancer\/prostate-cancer-esmo-clinical-guidelines\/","title":{"rendered":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"3537\" class=\"elementor elementor-3537\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9ec2946 e-flex e-con-boxed e-con e-parent\" data-id=\"9ec2946\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-dc7db21 elementor-widget elementor-widget-spacer\" data-id=\"dc7db21\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-a468e88 e-flex e-con-boxed e-con e-parent\" data-id=\"a468e88\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-985f5e4 e-con-full e-flex e-con e-child\" data-id=\"985f5e4\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-76708e9 e-con-full e-flex e-con e-child\" data-id=\"76708e9\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3446fbb elementor-widget elementor-widget-heading\" data-id=\"3446fbb\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment\nand follow-up<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-381f928 elementor-widget elementor-widget-text-editor\" data-id=\"381f928\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: left;\"><span class=\"fontstyle0\">Subclinical prostate cancer is common in men <\/span><span class=\"fontstyle2\">&gt;<\/span><span class=\"fontstyle0\">50 years Population-based screening of men aged between 55 and 69 years, using prostate-speci<\/span><span class=\"fontstyle3\">fi<\/span><span class=\"fontstyle0\">c antigen (PSA) testing, has been evaluated.<\/span><span class=\"fontstyle0\">1 <\/span><span class=\"fontstyle0\">After a median follow-up of 16 years, the European screening trial demonstrated a 25% relative reduction in prostate cancer mortality. However, 570 men needed to be invited for screening and 18 patients needed to be treated to prevent one death from prostate cancer, and there was no effect on overall survival (OS). Risk-adapted early detection of prostate cancer using a baseline PSA has been evaluated in retrospective cohort studies. Men with a PSA <\/span><span class=\"fontstyle2\">&gt;<\/span><span class=\"fontstyle0\">1 ng\/ml at 40 years or <\/span><span class=\"fontstyle2\">&gt;<\/span><span class=\"fontstyle0\">2 ng\/ml at 60 years are at increased risk of prostate cancer metastasis or death from prostate cancer<\/span><span class=\"fontstyle0\">\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-63cf7af e-con-full e-flex e-con e-child\" data-id=\"63cf7af\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4bf1600 elementor-widget elementor-widget-image\" data-id=\"4bf1600\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"689\" height=\"889\" src=\"https:\/\/uro-med.ir\/prostate-cancer\/wp-content\/uploads\/2025\/05\/esmo.jpg\" class=\"attachment-large size-large wp-image-4245\" alt=\"\" srcset=\"https:\/\/uro-med.ir\/prostate-cancer\/wp-content\/uploads\/2025\/05\/esmo.jpg 689w, https:\/\/uro-med.ir\/prostate-cancer\/wp-content\/uploads\/2025\/05\/esmo-388x500.jpg 388w, https:\/\/uro-med.ir\/prostate-cancer\/wp-content\/uploads\/2025\/05\/esmo-233x300.jpg 233w\" sizes=\"(max-width: 689px) 100vw, 689px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d7f9baa elementor-align-center elementor-widget elementor-widget-button\" data-id=\"d7f9baa\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/uro-med.ir\/prostate-cancer\/wp-content\/uploads\/2025\/05\/PIIS0923753420398987.pdf\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">download<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Subclinical prostate cancer is common in men &gt;50 years Population-based screening of men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been evaluated.1 After a median follow-up of 16 years, the European screening trial demonstrated a 25% relative reduction in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[],"class_list":["post-3537","post","type-post","status-publish","format-standard","hentry","category-articles"],"_links":{"self":[{"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/posts\/3537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/comments?post=3537"}],"version-history":[{"count":33,"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/posts\/3537\/revisions"}],"predecessor-version":[{"id":4261,"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/posts\/3537\/revisions\/4261"}],"wp:attachment":[{"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/media?parent=3537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/categories?post=3537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/uro-med.ir\/prostate-cancer\/wp-json\/wp\/v2\/tags?post=3537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}